XBI240920P43000
- 0.54
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'
SPDR S&P Biotech ETF Options Spot-On: On September 19th, 109.02K Contracts Were Traded, With 1 Million Open Interest
On September 19th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 109.02K options for the day, of which put options accounted for 19.38% of the total
Behind the Scenes of Amgen's Latest Options Trends
Wells Fargo's 'Value Equity List' – Stocks With Potential That Trade at a Discount
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
Halozyme Cut to Neutral at J.P. Morgan on Valuation
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Incyte, Syndax Report Publication Of Data From Pivotal AGAVE-201 Trial Of Niktimvo; Trial Met The Primary Endpoint Across All Cohorts
SPDR S&P Biotech ETF Options Spot-On: On September 18th, 131.66K Contracts Were Traded, With 933.6K Open Interest
On September 18th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 131.66K options for the day, of which put options accounted for 31.04% of the total
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
10 Health Care Stocks With Whale Alerts In Today's Session
28 Top Rated U.S. Growth Stocks Month-to-date in Anticipation of Fed Cuts
Incyte Downgraded at Truist on Jakafi Patent Cliff
SPDR S&P Biotech ETF Options Spot-On: On September 17th, 82,840 Contracts Were Traded, With 904.7K Open Interest
On September 17th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 82,840 options for the day, of which put options accounted for 33.05% of the total
What the Options Market Tells Us About Viking Therapeutics
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Incyte Closes 5% Higher Bolstered by Zynyz Data, Guggenheim Note
Incyte Shares Are Trading Higher After B of A Securities and Guggenheim Raised Their Respective Price Targets on the Stock.